Literature DB >> 21269598

Renal dysfunction and barttin expression in Bartter syndrome Type IV associated with a G47R mutation in BSND in a family.

C W Park1, J H Lim, D-Y Youn, S Chung, M-H Lim, Y K Kim, Y S Chang, J-H Lee.   

Abstract

Bartter syndrome (BS) Type IV, associated with a G47R mutation in the BSND gene, is known to result in a mild renal phenotype. However, we report here on three brothers with varying degrees of renal dysfunction from mild to end-stage renal disease associated with renal barttin and ClC-K expression. The brothers had histories of polyhydramnios, prematurity, polyuria, deafness, and small body size. Laboratory findings showed hypokalemic metabolic alkalosis, normotensive hyperreninemic hyperaldosteronism, and an increased urinary excretion of sodium, potassium and chloride, consistent with BS Type IV. Microscopic examination of renal tissue showed hyperplasia of cells at the juxtaglomerular apparatus with dilated atrophic tubules and tubulointerstitial fibrosis. A weak barttin signal related to CIC-K expression in the cytoplasm of tubule cells, but not the basement membrane, was noted. A sequence analysis of the BSND gene showed that the affected males were homozygous for a missense G47R mutation in exon 1 of BSND. These findings suggest that the G47R mutation results in a dramatic decrease in barttin expression, which appears to be related to the location of CIC-K being changed from the basement membrane to the cytoplasm in the tubule and might have varying effects on renal function associated with factors other than this gene.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21269598

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  2 in total

1.  Human CLC-K Channels Require Palmitoylation of Their Accessory Subunit Barttin to Be Functional.

Authors:  Kim Vanessa Steinke; Nataliya Gorinski; Daniel Wojciechowski; Vladimir Todorov; Daria Guseva; Evgeni Ponimaskin; Christoph Fahlke; Martin Fischer
Journal:  J Biol Chem       Date:  2015-05-26       Impact factor: 5.157

2.  Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics.

Authors:  Joao A Paulo; Fiona E McAllister; Robert A Everley; Sean A Beausoleil; Alexander S Banks; Steven P Gygi
Journal:  Proteomics       Date:  2014-10-18       Impact factor: 3.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.